v3.26.1
Segment Reporting (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]        
Revenues $ (0) $ 39,990
Total research and development expense 2,649,673 677,332 3,936,009 1,675,554
Advisory fees – related parties 3,586,575 4,946,575 11,737,806
Legal and professional 1,286,167 520,364 2,474,387 1,477,909
Employee compensation expenses 268,797 163,887 458,025 334,160
Amortization of debt issuance 167,951 192,249 360,116 360,200
Investor relations 56,810 226,766 104,322 771,073
Stock based compensation 5,651,913 3,526,076 8,384,311 20,923,850
Other general and administrative expense 569,952 593,609 821,920 728,514
Interest expense 234,370 48,750 1,216,994 357,672
Loss on change in fair value of derivative liability related to Series A preferred stock 61,321 61,321
Gain on change in fair value of derivative liability     (2,801)
Other expense 189,627 (240,138) 834,228 (240,138)
Interest and other income (483,112) (28,725) (535,431) (80,424)
Net loss (14,240,044) (5,680,170) (23,059,976) (38,006,186)
NEO100 [Member]        
Segment Reporting [Line Items]        
Total research and development expense 998,369 109,166 1,881,023 688,628
NEO100-02 [Member]        
Segment Reporting [Line Items]        
Total research and development expense 304,244 93,326 409,338 201,787
NEO212 [Member]        
Segment Reporting [Line Items]        
Total research and development expense 592,757 279,074 861,334 455,629
NEO216 [Member]        
Segment Reporting [Line Items]        
Total research and development expense 75,336 75,336
Pediatric [Member]        
Segment Reporting [Line Items]        
Total research and development expense 147,273 50,178 167,009 99,010
Laboratory [Member]        
Segment Reporting [Line Items]        
Total research and development expense 460,655 107,465 470,930 192,377
Other [Member]        
Segment Reporting [Line Items]        
Total research and development expense $ 71,039 $ 38,123 $ 71,039 $ 38,123